Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7944 results

Sort By:

Study of LP-184 in Patients with Advanced Solid Tumors

Study ID: NCT05933265
Start Date: 2023-06-09
End Date: 2025-09-09
Study Type

Interventional

Study Phase

Phase2

No. of Participants

175

Intervention / Treatment

LP-184

Spironolactone

Flapberry

Sponsor

Lantern Pharma Inc.

Source: clinicaltrials.gov

Share:
Add to list

Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas

Study ID: NCT06132165
Start Date: 2024-03-01
End Date: 2024-10-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

30

Intervention / Treatment

Deoxycholic Acid

Polidocanol

1064nm Nd:YAG laser

755nm Alexandrite Laser

Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

Combined Oral Contraceptive Pill and Resistance Starch

Study ID: NCT06852365
Start Date: 2025-04
End Date: 2028-04
Study Type

Interventional

Study Phase

Phase2

No. of Participants

100

Intervention / Treatment

wheat dextrin

Oral Contraceptives, Low-Dose

Maltodextrin

Sponsor

University of Pennsylvania

Source: clinicaltrials.gov

Share:
Add to list

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Study ID: NCT03996265
Start Date: 2019-06-27
End Date: 2025-12-30
Study Type

Interventional

Study Phase

Phase3

No. of Participants

422

Intervention / Treatment

Biospecimen Collection

Bupropion Hydrochloride Controlled-release

Placebo Administration

Quality-of-Life Assessment

Administration questionnaire

Sponsor

University of Rochester NCORP Research Base

Source: clinicaltrials.gov

Share:
Add to list

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Study ID: NCT05948865
Start Date: 2023-06-06
End Date: 2025-12-12
Study Type

Interventional

Study Phase

Phase1

No. of Participants

102

Intervention / Treatment

CPO301

Sponsor

Conjupro Biotherapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Study of Tazemetostat in Lymphoid Malignancies

Study ID: NCT05983965
Start Date: 2024-09-05
End Date: 2029-12
Study Type

Interventional

Study Phase

Phase1

No. of Participants

30

Intervention / Treatment

Tazeetostat

Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Study ID: NCT05691465
Start Date: 2023-12-27
End Date: 2025-11-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

30

Intervention / Treatment

Biospecimen Collection

Computed Tomography

Gallium GA 68-Dotate

Lutetium Lu 177 dotatate

Positron Emission Tomography

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Facilitating Advance Care Planning Discussions for People With Advance Cancer

Study ID: NCT06061965
Start Date: 2024-07-09
End Date: 2025-07-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

18

Intervention / Treatment

Web-based resilience-building intervention

Sponsor

University of Illinois at Chicago

Source: clinicaltrials.gov

Share:
Add to list

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Study ID: NCT04471974
Start Date: 2021-01-26
End Date: 2027-04-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

54

Intervention / Treatment

Bet Bromodomain Inhibitor Zen-3694

Enzalutamid

Pembrolizumab

Sponsor

Rahul Aggarwal

Source: clinicaltrials.gov

Share:
Add to list

Strategic Targeting for Optimal Prevention of Cancer

Study ID: NCT03897374
Start Date: 2022-03-26
End Date: 2027-12-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

120000

Intervention / Treatment

Genetic Testing

Sponsor

ClinLogic LLC

Source: clinicaltrials.gov

Share:
Add to list